

H5C

AACR *American Association for Cancer Research*

ANNUAL MEETING OF THE
AMERICAN ASSOCIATION
FOR CANCER RESEARCH

93rd Annual Meeting

April 6-10, 2002 • San Francisco, California

Volume 43 • March 2002

In joint sponsorship with the Keck School of Medicine of the University of Southern California

The premier meeting for cancer research in the post-genomic era

Featuring the latest developments in basic, translational, and clinical cancer research

HEALTH SCIENCES LIBRARY
UNIVERSITY OF WISCONSIN

MAR 22 2002

1305 Linden Drive
Madison, WI 53706

Proceedings

Proceedings of the American Association for Cancer Research

93rd
Annual Meeting

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Officers

PresidentWaun Ki Hong
 President-ElectSusan Band Horwitz
 TreasurerBayard D. Clarkson
 Past PresidentTom Curran
 Chief Executive OfficerMargaret Foti

Board of Directors

Until 2002
 Mina J. Bissell
 Michael B. Kastan
 Edison T. Liu
 Frank J. Rauscher, III

Until 2003
 Michael C. Christian
 Lorraine J. Gudas
 William G. Nelson, V
 Peter K. Vogt
 Geoffrey M. Wahl

Until 2004
 Frederick R. Appelbaum
 Ronald A. DePinho
 Tyler E. Jacks
 George F. Vande Woude
 Barbara L. Weber

Address inquiries to the Office of the American Association for Cancer Research, Inc. (AACR), Public Ledger Building, Suite 826, 150 S. Independence Mall West, Philadelphia, PA 19106-3483 [Telephone: (215) 440-9300; Fax: (215) 440-9313].

The *Proceedings of the American Association for Cancer Research* is printed for the AACR by Cadmus Professional Communications, Linthicum, MD 21090-2908 and is included in the membership dues for active and associate members. Volume 43 of the *Proceedings of the American Association for Cancer Research* (ISSN 0197-016X) succeeds Volume 42 of the *Proceedings of the American Association for Cancer Research*. The *Proceedings* may be obtained at a price of \$55.00 through registration at the Annual Meeting of the American Association for Cancer Research, April 6-10, 2002, or ordered by writing to: AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202 [Telephone: (800) 633-4931 or (205) 995-1567; Fax: (205) 995-1588]. Add \$6.00 for shipping for orders outside the U.S.; expedited delivery rates are available on request.

The *Proceedings of the American Association for Cancer Research* is copyrighted © 2002 by the AACR. All rights reserved. Redistribution or resale of the *Proceedings* or of any materials in the *Proceedings*, whether in machine readable, other electronic, or any other form, is prohibited. Reproduction for advertising or promotional purposes, or republication in any form, may be permitted only under license from the AACR. Any reproduction, whether electronic or otherwise, of abstracts beyond that permitted by copyright law must be authorized in writing in advance by the AACR. Requests to reproduce abstracts will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate fee. Reproduction requests must include a brief description of intended use. Third parties should also obtain the approval of the authors before corresponding with the AACR. Failure to comply with the foregoing restrictions and unauthorized duplication of any portion of these materials are a violation of applicable laws and may be subject to criminal prosecution and civil penalties.

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., or by Cadmus Professional Communications for the opinions expressed by the contributors herein.

differentiation of myeloid leukemia cell lines (NB4, HL-60 and U937). SS was identified in our recent studies as a potent inhibitor of PTPases. Herein, we present data demonstrating that SS (250 $\mu\text{g/ml}$, 6 days) induced 87% of NB4 cells to reduce nitroblue tetrazolium (NBT), in comparison to the 90% induced by ATRA (1 μM , 6 days). SS-induced NB4 cell differentiation was confirmed by increased CD11b expression and associated with growth arrest at S phase and increased cell death. Our results showed further that SS-induced NB4 differentiation was irreversible and required continuous drug exposure for optimal induction. Moreover, SS (400 $\mu\text{g/ml}$, 6 days) induced 60% and 55% of NBT-positive cells in HL-60 and U937 cell lines, which were augmented in the presence of GM-CSF (2 ng/ml) to levels (85% and 81%, respectively) comparable to those induced by ATRA. These results provide the first evidence of a differentiation induction activity of PTPase inhibitor SS in myeloid leukemia cell lines and suggest its potential therapeutic use in myeloid leukemia. Since SS induces differentiation via targeting PTPases, a mechanism distinct from that of ATRA, it may be particularly useful in AML cases unresponsive or developed resistance to ATRA.

#356 NAD(P)H:quinone oxidoreductase (NQO1)-dependent and -independent cytotoxicity of potent quinone cdc25 phosphatase inhibitors. Yusheng Han, Hongmei Shen, Brian Carr, John S. Lazo, and Su-Shu Pan. *University of Pittsburgh Cancer Institute, Pittsburgh, PA, and University of Pittsburgh, Pittsburgh, PA.*

A vitamin K analogue, compound 5 (Cpd5, a thioethanol naphthoquinone), inhibits oncogenic Cdc25 phosphatases, and arrests cell cycle progression at both G1 and G2/M. Recently, we evaluated >10,000 compounds in the NCI chemical repository for *in vitro* inhibition against recombinant human Cdc25B phosphatase and identified a quinone substructure in many of the active compounds. Bioreductive enzymes in cells, however, are known to reduce various quinones resulting in either detoxification or activation. Therefore, we used an isogenic set of human colon cancer cell lines to evaluate the effect of NQO1 on the cytotoxic activity of Cpd5 and the two most potent phosphatase inhibitors from the repository: NSC 95397 (a bis-thioethanol naphthoquinone) and NSC 663284 (a quinolinedione). The two cancer cell lines used were HCT116, which has intermediate NQO1 activity, and its mitomycin C-resistant sub-line HCT116-R30A (R30A), which has minimum NQO1 activity. Cell survival was measured by colony formation after 7 days drug exposure. Cell cycle arrest was evaluated by flow cytometry after 6 hr drug exposure. Cpd5 had an IC_{50} of $2.2 \pm 0.3 \mu\text{M}$ for HCT116 and $0.23 \pm 0.05 \mu\text{M}$ for R30A, i.e. a 10-fold difference. Inclusion of dicoumarol (10 μM), an inhibitor of NQO1, decreased the IC_{50} of Cpd5 for HCT116 to $0.24 \pm 0.04 \mu\text{M}$, but had no effect on R30A. In contrast, HCT116 and R30A cells were equally inhibited by NSC 95375 with IC_{50} s of $1.4 \pm 0.3 \mu\text{M}$ and $1.3 \pm 0.2 \mu\text{M}$, respectively. Similarly, HCT116 and R30A cells were equally inhibited by NSC 663284 with IC_{50} s of $2.4 \pm 0.3 \mu\text{M}$ and $2.6 \pm 0.5 \mu\text{M}$, respectively. All three compounds blocked the two cell lines at the G2/M phase transition, consistent with cdc25 inhibition. Cpd5 at 2.5 μM arrested R30A cells at G2/M but 7.5 μM Cpd5 was needed to arrest HCT116 cells to a similar degree. NSC 95375 and 663284 arrested cell cycle progression at G2/M of HCT116 and R30A cells similarly, and did so in a concentration-dependent manner between 2.5 and 7.5 μM . Our data imply that NQO1 in HCT116 cells protected cells from the action of Cpd5, probably by the reduction of Cpd5 to a less active hydroxylquinone. In contrast, both NSC 95397 and 663284 displayed cytotoxicity that was independent of NQO1 levels. (Support: NCI CA61862 and CA78039)

#357 Antitumor and anticarcinogenic action of Cpd 5: A new class of protein phosphatase inhibitor. Siddhartha Kar, Meifang Wang, Zhenggang Ren, Xiangbai Chen, and Brian I. Carr. *University of Pittsburgh, Pittsburgh, PA.*

Background: We have chemically synthesized a new class of inhibitors of dual specificity phosphatases (DSP), which play an important role in cell cycle and signal transduction. Cpd 5 or 2-(2-mercaptoethanol)-3-methyl-1,4-naphthoquinone is one of the most potent. It inhibits DSPs (especially the Cdc25 family) in tissue culture cells and induces tyrosine phosphorylation of various DSP substrates, including Cdk5 and inhibits cell growth both *in vitro* and *in vivo* (JBC 270:28304, 1995; Proc. AACR 39:224, 1998). Purpose: In this study we evaluated (a) the antitumor and (b) the anticarcinogenic activity of Cpd 5 for the first time. Methods: (a) JM1 hepatomas were grown in 2 month old Fischer male rats by subcutaneous injection on the back or intra-portally in the liver. Rats were treated with Cpd 5 by intratumor, subcutaneous (nearby site), intramuscular (distant site), or intraperitoneal injection, either as a single high acute dose or chronically as several low doses. (b) Rats were injected intraperitoneally with a single dose of the carcinogen N-Nitrosodimethylamine (DEN). Immunostained liver sections for glutathione-S-transferase-pi (GST-pi) detected pre-neoplastic foci after 3 weeks. Cpd 5 was injected subcutaneously or intraperitoneally two weeks after DEN as a single high acute dose or chronically as several low doses. Results: (a) Cpd 5 had significant inhibitory effect on both intrahepatic (14% of control, $p < 0.00000008$) and subcutaneous (33% of control, $p < 0.00008$) tumor growth and also had significant inhibitory effect when injected intramuscularly at a site distant from the tumor (50% of control, $p < 0.002$). There was no significant difference between the effects after acute or chronic injections. However, toxicity was much lower with chronic treatment. (b) The number of enzyme altered foci was also significantly

reduced when rats were treated with acute (40% of control, $p < 0.00002$) or chronic (50% of control, $p < 0.02$) Cpd 5. Conclusions: Cpd 5 had significant inhibitory effect on growth of tumors and foci.

#358 Bosentan, a novel endothelin-A and -B receptor antagonist inhibits proliferation of malignant melanoma cells. Aleksandar Sekulic, Padma Suresh, Mark R. Pittelkow, and Svetomir N. Markovic. *Mayo Foundation, Rochester, MN.*

Here we tested a feasibility of endothelin (ET) receptor blockade with a dual endothelin-A and -B receptor (ETR-A and ETR-B) antagonist, Bosentan, as a novel therapeutic approach for malignant melanoma. ETs are 21aa peptides primarily produced by endothelial cells and implicated in a variety of physiological functions. Binding of ET to ETR-A on vascular structures potentially stimulates angiogenesis and, thus, likely plays an important role in growth of multiple cancers. Activation of ETR-Bs, among other things, regulates melanocyte development and function. We first examined patterns of ETR subtype expression on six established melanoma cell lines using flow cytometry and immunocytochemistry. Following this sections of primary and metastatic melanoma tissues were evaluated for ETRA/ETRB expression by immunohistochemistry. To test functional effects Bosentan on melanoma cell proliferation, six melanoma cell lines were subjected to standard 3H-thymidine incorporation assays in presence or absence of various concentrations of Bosentan. All examined melanoma tissues (2 primary, 9 metastatic) express ETRB, albeit to different levels, whereas ETRA was expressed to low levels in only 3 metastatic tumors. In functional assays Bosentan inhibited proliferation of all examined cell lines with the IC_{50} ranging between 7 and 40 $\mu\text{g/ml}$. Our results suggest that malignant melanocytes express functional ETRs, and their treatment with Bosentan leads to significant growth inhibition. Concurrent inhibition of ETR-A and ETR-B *in vivo* by low toxicity, orally available inhibitor Bosentan might therefore prove useful as a novel mode of anti-melanoma therapy through simultaneous inhibition of cancer cell growth and process of angiogenesis.

#359 In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Terence O'Reilly, Juliane Vaxelaire, Melanie Muller, Heinz-Herbert Fiebig, Marc Hattenberger, and Heidi A. Lane. *Business Unit Oncology, Novartis Pharma AG, Basel, Switzerland, and Oncotest GmbH, Freiburg, Germany.*

RAD001 is a hydroxyethyl ether derivative of rapamycin that is orally bioavailable. RAD001 has demonstrated *in vitro* anti-proliferative activity against a panel of human tumor lines. For *in vivo* testing, tumor-bearing nude mice were administered RAD001 in a variety of doses and schedules. Tumors were established by transplantation of fragments generated from injection of cells, or by transplantation of fragments from stabilized tumors originating from surgically removed human tumors. When administered once daily p.o., at doses ranging from 0.5-5.0 mg/kg/day, RAD001 was a potent inhibitor of tumor growth in 10 different xenograft models of human tumors (including pancreatic, colon, epidermoid, lung and melanoma). In general, RAD001 was well tolerated and better tolerated in mouse xenograft models than standard cytotoxic agents (i.e. doxorubicin and 5-fluorouracil), while possessing similar antitumor activity. Only one instance of *in vivo* resistance has been observed (MAXF 401 mammary xenograft model), otherwise the activity of RAD001 was generally inhibition of tumor growth (persistent regressions in one tumor line, T/C values of 9 to 45 % in 8 tumor lines). Xenograft models sensitive to RAD001 treatment included tumors exhibiting comparative resistance *in vitro* (KB-31 and HCT116). Persistent tumor regressions (41 %) were observed in a line displaying sensitivity to RAD001 *in vitro* (A549). Pharmacokinetic analyses, following a 5 mg/kg administration, indicated rapid uptake into plasma (C_{max} 2513 ng/ml; T_{max} 1 h), but the time to C_{max} was delayed in tumors (C_{max} 102 ng/g; T_{max} 2 h). Elimination from the tumor ($t_{1/2}$, 16 hr) was apparently slower than for plasma ($t_{1/2}$, 7.5 hr). RAD001 levels were above the IC_{50} of A549 cells for a 72 h period. Interestingly, tumor RAD001 levels, following a single 5 mg/kg administration, never exceeded the *in vitro* antiproliferative IC_{50} for either KB-31 or HCT116 cells; despite the sensitivity of these lines *in vivo*. From these observations, and given the extreme sensitivity of endothelial cells to RAD001, it is plausible that RAD001 may not only act on tumor cells but may also affect angiogenesis. Taken together, these data support the application of RAD001 as an antitumor agent.

#360 Discovery of anticancer agents from sponge-associated fungi. Frederick A. Valeriote, Karen Tenney, Charles Grieshaber, Halina Pietraszkiewicz, Akiko Amagata, Taro Amagata, Jeff Gautschi, Joseph Media, Joseph Stayanoff, Richard Wiegand, and Phil Crews. *Henry Ford Health System, Detroit, MI, and University of California Santa Cruz, Santa Cruz, CA.*

We have evaluated 1,112 extracts (from 660 sponge-associated fungi) for assessment of potential anticancer activity. Both broth and mycelia extracts were assayed in most cases. Each sample was assayed *in vitro* against up to 8 cell types (murine and human) in a disk diffusion/ clonogenic assay. From these results, the samples were assigned into one of 4 categories: Inactive (79% of the extracts), Equally active across cell types (16% of the extracts), Equally active and potent (9 extracts or 1%), and Solid tumor selective (42 extracts or 3.8%). The equally active and potent category is studied further since solid tumor selective compounds might exist in the extract but be concealed by one or more potent, cytotoxic compounds. Further, a novel, potent compound could form the basis for analog synthesis in an attempt to develop an active anticancer agent. One